PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...

Report with the AI impact on market trends - The global predictive maintenance (PDM) market size is estimated to grow by USD ...

Administration for these structures requires compliance, which now includes the U.S. Corporate Transparency Act (the CTA).

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...

PTC Therapeutics (PTCT) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150M ...

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

The U.S. Food and Drug Administration has approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for the ...